Truist on Cytokinetics (CYTK): 'We See Best In Class Potential for aficamten'
Tweet Send to a Friend
Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $60.00 price target on Cytokinetics (NASDAQ: CYTK)The analyst comments "SEQUOIA-HCM ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
